New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
10:25 EDTCVD, CVD, EBS, EBS, CI, CI, BSX, BSX, BMY, BMY, AMGN, AMGN, ABT, ABT, HNT, HNT, SHPG, SHPG, REGN, REGN, PDCO, PDCO, VRTX, VRTXJPMorgan to host a conference
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 14 at 10:30 am; not all presentations may be webcasted. Webcast Link
News For CVD;PDCO;REGN;SHPG;HNT;ABT;AMGN;BMY;BSX;CI;EBS;VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 19, 2015
07:54 EDTBSXBoston Scientific reports positive data from EVOLVE trial
Subscribe for More Information
07:51 EDTAMGNFDA PDUFA Date for Amgen's Blinatumomab is May 19, 2015
Subscribe for More Information
07:45 EDTBMYJacobs Engineering receives contract from Bristol-Myers
Jacobs Engineering (JEC) received a contract from Bristol-Myers Squibb Company (BMY) to provide construction management services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Jacobs is also providing architectural and engineering services for the facility, which is being built to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
07:06 EDTEBSEmergent BioSolutions signs manufacturing agreement with Prometic Life Sciences
Subscribe for More Information
May 18, 2015
12:34 EDTREGNRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
11:23 EDTABTFitch downgrades Abbott's L-T IDR to A; outlook revised to stable
Subscribe for More Information
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
May 15, 2015
12:13 EDTAMGNThird Point gives quarterly update on stakes
NEW STAKES: Yum! Brands (YUM), NXP Semiconductors (NXPI), FedEx (FDX), McKesson (MCK), and J M Smucker (SJM). INCREASED STAKES: Actavis (ACT), Roper Technologies (ROP), Delta Air Lines (DAL), and FleetCor Technologies (FLT). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Phillips 66 (PSX), eBay (EBAY), and Anheuser Busch Inbev SA (BUD). LIQUIDATED STAKES: Alibaba Group (BABA), Citigroup (C), EMC Corporation (EMC), Anglo American (AAL), and Williams Companies (WMB).
11:08 EDTSHPGOmega Advisors gives quarterly update on stakes
NEW STAKES: Targa Resources (TRGP), Targa Resources Partners (NGLS), Humana (HUM), Dow Chemical (DOW), and Twenty-First Century Fox (FOXA). INCREASED STAKES: Kinder Morgan (KMI), Chimera Investment Corporation (CIM), AerCap Holdings (AER), Shire (SHPG), and KKR & Co. (KKR). DECREASED STAKES: eBay (EBAY), Altisource Portfolio Solutions (ASPS), Caesars Entertainment (CZR), Navient (NAVI), and TerraForm Power (TERP). LIQUIDATED STAKES: HCA Holdings (HCA), Gilead (GILD), Cabot Oil & Gas (COG), and Apple (AAPL).
10:29 EDTBSXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTVRTX, BSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:15 EDTREGNRegeneron target upped to $550 at Credit Suisse citing growth potential
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $450 from $427 at JPMorgan
JPMorgan said it is "increasingly confident" in dupilumab's longer-term prospects in asthma ahead of the full Phase 2b results. The firm believes the drug's peak sales could top $4B. JPMorgan keeps a Neutral rating on Regeneron, however, saying its valuation already reflects blockbuster sales for Eylea, Praluent, sarilumab and dupilumab. It raised its price target for the name to $450 from $427.
05:32 EDTAMGNAmgen presents first Phase 2 data for AMG 334
Subscribe for More Information
May 14, 2015
11:03 EDTBMYBristol-Myers treatment of progressive supranuclear palsy granted orphan status
Subscribe for More Information
10:41 EDTBMY, AMGNAnalysts upbeat on Amgen's Kyprolis after ASCO abstracts
Subscribe for More Information
09:41 EDTBSX, ABTLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
09:22 EDTBMYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:09 EDTBMYBristol-Myers down 1.3% after release of ASCO abstracts
Subscribe for More Information
07:44 EDTAMGNInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use